Cited by 43Acute Ischemic Stroke ManagementNeurological Disorders and TreatmentsLipoproteins and Cardiovascular Health

Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2

Kilic, Ü., Bassetti, C.L., Kilic, E., Xing, H., Wang, Z., Hermann, D.M.·2005·Neuroscience

Abstract

After recent clinical trials, statins have gained increasing significance in secondary stroke prevention. From experimental studies, it is well established that statins have beneficial action when delivered prophylactically prior to a stroke. Conversely, much less is known about the effects of statins on injury development when delivered after ischemia. We here examined the effects of a post-ischemic delivery of rosuvastatin (0.5, 5 or 20 mg/kg, administered i.p. immediately after reperfusion onset), a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on brain injury and cell signaling after focal cerebral ischemia, induced by 90 min of intraluminal middle cerebral artery occlusion in mice. In animals receiving normal saline, 0.5 or 5 mg/kg rosuvastatin, middle cerebral artery occlusions resulted in reproducible brain infarcts at 24 h after reperfusion onset, which did not differ in size. However, rosuvastatin, administered at higher doses (20 mg/kg), reduced infarct volume at 24 and 48 h after ischemia (by 34+/-16% and 18+/-3%, respectively, P<0.05). Western blots revealed that rosuvastatin decreased phosphorylated extracellular-regulated kinase-1/-2 and reduced activated caspase-3 levels in ischemic brain areas, while endothelial NO synthase expression, p38 and Jun kinase phosphorylation were not influenced by the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Rosuvastatin also significantly diminished expression levels of inducible NO synthase in the ischemic brain. Our results indicate that rosuvastatin may have utility not only as stroke prophylaxis but also as acute therapy inhibiting executive cell death pathways.

Integrity signals

Registry

Crossref · 10.1016/j.neuroscience.2005.04.063

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

1 of the 35 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Kilic, Ü., Bassetti, C. L., Kilic, E., Xing, H., Wang, Z., & Hermann, D. M.
Affiliations
University Hospital Zurich (CH)
Venue
Neuroscience
Publisher
Elsevier BV
Published
2005-01
Volume
134
Issue
3
Pages
901-906
ISSN
0306-4522 (ISSN-L)
OpenAlex
W2013105910
Cited by
43
References
35
Citations by year
2026: 1 · 2025: 1 · 2019: 1 · 2017: 1 · 2015: 3 · 2014: 3 · 2013: 3 · 2012: 8
FWCI
2.87
Type
journal article
Language
en
Open access
closed
Locations
  • Neuroscience (publishedVersion)
  • PubMed (publishedVersion)
Funders
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Topics
  • Health Sciences › Medicine › Epidemiology › Acute Ischemic Stroke Management
  • Life Sciences › Neuroscience › Neurology › Neurological Disorders and Treatments
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
Keywords
rosuvastatin, statins, focal cerebral ischemia, middle cerebral artery occlusion, ERK1/2 phosphorylation, caspase-3, neuronal cell death, infarct size, inducible nitric oxide synthase, p38 MAPK, Jun kinase, secondary stroke prevention, acute stroke therapy
MeSH terms
Rosuvastatin Calcium, Animals, Cell Count, Brain Ischemia, Dose-Response Relationship, Drug, Fluorobenzenes, Male, Mice, Inbred C57BL, Pyrimidines, Staining and Labeling, Sulfonamides, Time Factors, Blotting, Western, Reperfusion, Laser-Doppler Flowmetry, Nitric Oxide Synthase, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Mitogen-Activated Protein Kinase 1, Infarction, Middle Cerebral Artery, Brain Infarction, Mitogen-Activated Protein Kinase 3, Mice, Nitric Oxide Synthase Type II, Nitric Oxide Synthase Type III

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review